PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7591064-0 1995 Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis. Superoxides 49-59 growth hormone 1 Homo sapiens 0-14 15935981-0 2005 Perioperative treatment with human growth hormone down-regulates apoptosis and increases superoxide production in PMN from patients undergoing infrarenal abdominal aortic aneurysm repair. Superoxides 89-99 growth hormone 1 Homo sapiens 35-49 9401546-4 1997 Other effects of GH on the immune system appear to be direct, such as priming monocytes for enhanced production of hydrogen peroxide in response to phorbol esters, and stimulating neutrophils to secrete superoxide anions associated with enhanced phagocytic activity. Superoxides 203-220 growth hormone 1 Homo sapiens 17-19 15370188-4 2004 The change in neutrophil superoxide generation was significantly correlated with the change in growth hormone concentration after Qi-training (p < .01). Superoxides 25-35 growth hormone 1 Homo sapiens 95-109 15370188-5 2004 These data indicate that, in elderly men, Qi-training enhances superoxide generation by neutrophils, possibly via the changes in plasma growth hormone concentration. Superoxides 63-73 growth hormone 1 Homo sapiens 136-150 8878069-0 1996 Superoxide anion release from neutrophils in growth hormone deficient adults before and after replacement therapy with recombinant human growth hormone. Superoxides 0-16 growth hormone 1 Homo sapiens 45-59 8878069-0 1996 Superoxide anion release from neutrophils in growth hormone deficient adults before and after replacement therapy with recombinant human growth hormone. Superoxides 0-16 growth hormone 1 Homo sapiens 137-151 8878069-8 1996 In growth hormone deficient subjects, formylpeptide-triggered release of superoxide anions from neutrophils was significantly suppressed by about 40% before treatment as compared to healthy control subjects. Superoxides 73-90 growth hormone 1 Homo sapiens 3-17 1490032-5 1992 Other functions of monocytes that are activated by growth hormone include release of superoxide anion and production of cytokines. Superoxides 85-101 growth hormone 1 Homo sapiens 51-65 8325540-6 1993 Homocysteine thiolactone is oxidized to sulfate by a process involving ascorbate, thioretinamide, and superoxide, under the control of thyroxine and growth hormone. Superoxides 102-112 growth hormone 1 Homo sapiens 149-163 2198842-3 1990 We have shown that growth hormone mimics one action of interferon-gamma (IFN-gamma) by augmenting the production of superoxide anion by macrophages and neutrophils. Superoxides 116-132 growth hormone 1 Homo sapiens 19-33 1310696-0 1992 Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. Superoxides 24-40 growth hormone 1 Homo sapiens 0-14 1310696-1 1992 Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O2-) secretion. Superoxides 146-162 growth hormone 1 Homo sapiens 18-32 1310696-1 1992 Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O2-) secretion. Superoxides 164-166 growth hormone 1 Homo sapiens 18-32 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 206-222 growth hormone 1 Homo sapiens 0-14 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 206-222 growth hormone 1 Homo sapiens 16-18 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 206-222 growth hormone 1 Homo sapiens 28-30 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 224-226 growth hormone 1 Homo sapiens 0-14 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 224-226 growth hormone 1 Homo sapiens 16-18 1847167-2 1991 Growth hormone (GH) and the GH-dependent growth promoting peptide, insulin-like growth factor-I (IGF-I), are both potent signals for priming human and porcine polymorphonuclear neutrophils (PMN) to secrete superoxide anion (O2-). Superoxides 224-226 growth hormone 1 Homo sapiens 28-30 1847167-10 1991 However, priming PMN by both GH and IGF-I required de novo protein synthesis, because cycloheximide completely abrogated enhanced O2- secretion that was caused by these growth factors. Superoxides 130-132 growth hormone 1 Homo sapiens 29-31 21691087-8 2011 In addition, NADPH oxidase subunit, gp91(phox) and GH receptors aggregated in membrane raft clusters, which produced O(2). Superoxides 117-121 growth hormone 1 Homo sapiens 51-53 19144554-6 2009 GH has several biological actions in the immune system: enhancing thymopoiesis and T cell development, modulating cytokine production, enhancing B cell development and antibody production, priming neutrophils and monocytes for superoxide anion secretion, enhancing neutrophil adhesion and monocyte migration and anti-apoptotic action. Superoxides 227-243 growth hormone 1 Homo sapiens 0-2